Crescent Biopharma Q3 2025 Earnings Report

Crescent Biopharma EPS Results

• Actual EPS: -$1.27
• Consensus EPS: -$1.01
• Beat/Miss: Missed by -$0.26
• One Year Ago EPS: N/A

Crescent Biopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Crescent Biopharma Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Crescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis. In parallel, Crescent is advancing an oncolytic adenovirus program engineered to selectively infect and lyse cancer cells, thereby releasing tumor antigens and amplifying systemic immune responses. Additional preclinical assets explore complementary mechanisms to address resistance in solid tumors.

Research and development activities are conducted primarily in the United States, leveraging a proprietary platform that integrates molecular engineering with immuno‐oncology expertise. Crescent collaborates with contract research organizations and academic institutions to optimize candidate selection, advance preclinical studies and prepare for clinical evaluation.

Founded in 2020 and headquartered in Woodland Hills, California, Crescent Biopharma is led by a management team and scientific advisory board with extensive experience in oncology drug discovery, biologics development and clinical operations. The company is focused on progressing its pipeline through IND-enabling studies and early‐phase clinical trials.